AstraZeneca plc Receives Buy Rating from Citigroup Inc. (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Citigroup Inc. in a report released on Wednesday. They currently have a GBX 4,900 ($83.89) price target on the stock. Citigroup Inc.’s price objective indicates a potential upside of 12.10% from the company’s current price.
AstraZeneca plc (LON:AZN) traded down 0.31% on Wednesday, hitting GBX 4371.00. The stock had a trading volume of 2,673,194 shares. AstraZeneca plc has a 1-year low of GBX 3086.50 and a 1-year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4363.72 and a 200-day moving average of GBX 4114.81. The company’s market cap is £55.118 billion.
A number of other analysts have also recently weighed in on AZN. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Tuesday. They now have a GBX 4,400 ($75.33) price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of AstraZeneca plc from GBX 4,850 ($83.03) to GBX 4,790 ($82.01) in a research note on Monday. They now have a “hold” rating on the stock. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, July 10th. They now have a GBX 4,800 ($82.18) price target on the stock. Seven equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company. AstraZeneca plc has an average rating of “Hold” and a consensus target price of GBX 4,063.37 ($69.57).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.